Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Relapse of Aplastic Anemia with Majority Donor Chimerism (Donor-Type Aplasia) Occurring Late after Bone Marrow Transplantation.

Shaw A, Passweg JR, De La Fuente J, Bajwa R, Stein J, Al-Zaben A, Halkes CJM, Norton A, Cummins M, Moppett JP, Shanap MA, Steward CG; Aplastic Anaemia Working Party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2019 Nov 13. pii: S1083-8791(19)30750-5. doi: 10.1016/j.bbmt.2019.11.010. [Epub ahead of print]

PMID:
31733299
2.

Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.

Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.

Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0600-z. [Epub ahead of print]

PMID:
31624377
3.

Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.

Loeff FC, van Egmond EHM, Moes DJAR, Wijnands C, Von Dem Borne PA, Veelken H, Falkenburg JHF, Jedema I, Halkes CJM.

Transpl Immunol. 2019 Dec;57:101209. doi: 10.1016/j.trim.2019.06.001. Epub 2019 Jun 14.

4.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

5.

Use of eltrombopag in aplastic anemia in Europe.

Ecsedi M, Lengline É, Knol-Bout C, Bosman P, Eikema DJ, Afanasyev B, Maschan A, Dreger P, Halkes CJM, Drexler B, Cortelezzi A, Drénou B, Patriarca A, Bruno B, Onofrillo D, Lanino E, Pulanic D, Serventi-Seiwerth R, Garnier A, Ljungman P, Bonifazi F, Giammarco S, Tournilhac O, Pioltelli P, Rovó A, Risitano AM, de Latour RP, Dufour C, Passweg J; EBMT SAA Working Party.

Ann Hematol. 2019 Jun;98(6):1341-1350. doi: 10.1007/s00277-019-03652-8. Epub 2019 Mar 26.

PMID:
30915499
6.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M, Spinelli O, Greco R, Crucitti L, Cieri N, Noviello M, Manfredi F, Montaldo E, Ostuni R, Naldini MM, Gentner B, Waterhouse M, Zeiser R, Finke J, Hanoun M, Beelen DW, Gojo I, Luznik L, Onozawa M, Teshima T, Devillier R, Blaise D, Halkes CJM, Griffioen M, Carrabba MG, Bernardi M, Peccatori J, Barlassina C, Stupka E, Lazarevic D, Tonon G, Rambaldi A, Cittaro D, Bonini C, Fleischhauer K, Ciceri F, Vago L.

Nat Med. 2019 Apr;25(4):603-611. doi: 10.1038/s41591-019-0400-z. Epub 2019 Mar 25.

PMID:
30911134
7.

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.

Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, Stölzel F, Altmann H, Bornhäuser M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C.

Nat Commun. 2019 Mar 25;10(1):1065. doi: 10.1038/s41467-019-08871-1.

8.

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.

van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF.

Front Immunol. 2018 Dec 18;9:3016. doi: 10.3389/fimmu.2018.03016. eCollection 2018.

9.

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Albano F, Lefrère F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Haematologica. 2019 Jun;104(6):1168-1175. doi: 10.3324/haematol.2018.204826. Epub 2018 Dec 6.

10.

Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.

Loeff FC, Rijs K, van Egmond EHM, Zoutman WH, Qiao X, Kroes WGM, Veld SAJ, Griffioen M, Vermeer MH, Neefjes J, Frederik Falkenburg JH, Halkes CJM, Jedema I.

Am J Hematol. 2019 Jan;94(1):93-102. doi: 10.1002/ajh.25337. Epub 2018 Nov 25.

11.

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, Risitano AM; Severe Aplastic Anaemia Working Party of the EBMT.

Am J Hematol. 2019 Jan;94(1):80-86. doi: 10.1002/ajh.25314. Epub 2018 Nov 25.

12.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Oct;97(10):1785-1795. doi: 10.1007/s00277-018-3396-4. Epub 2018 Jun 20.

13.

CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.

van der Heiden PLJ, van Egmond HM, Veld SAJ, van de Meent M, Eefting M, de Wreede LC, Halkes CJM, Falkenburg JHF, Marijt WAF, Jedema I.

Transpl Immunol. 2018 Aug;49:54-58. doi: 10.1016/j.trim.2018.04.003. Epub 2018 Apr 18.

PMID:
29679650
14.

High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.

Loeff FC, Falkenburg JHF, Hageman L, Huisman W, Veld SAJ, van Egmond HME, van de Meent M, von dem Borne PA, Veelken H, Halkes CJM, Jedema I.

J Immunol. 2018 Mar 15;200(6):2199-2208. doi: 10.4049/jimmunol.1701018. Epub 2018 Feb 2.

15.

Transplant results in adults with Fanconi anaemia.

Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, Dufour C; EBMT SAA WP.

Br J Haematol. 2018 Jan;180(1):100-109. doi: 10.1111/bjh.15006. Epub 2017 Nov 2.

PMID:
29094350
16.

Donor T-cell responses and disease progression patterns of multiple myeloma.

Eefting M, de Wreede LC, Von dem Borne PA, Halkes CJM, Kersting S, Marijt EWA, Putter H, Veelken H, Schetelig J, Falkenburg JHF.

Bone Marrow Transplant. 2017 Dec;52(12):1609-1615. doi: 10.1038/bmt.2017.201. Epub 2017 Oct 2.

PMID:
28967897
17.

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin.

van der Hem JGK, de Wreede LC, Brand A, Veelken H, Falkenburg JHF, Halkes CJM.

Haematologica. 2017 Oct;102(10):e382-e383. doi: 10.3324/haematol.2017.171215. Epub 2017 Jul 13. No abstract available.

18.

Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.

van Balen P, van Luxemburg-Heijs SAP, van de Meent M, van Bergen CAM, Halkes CJM, Jedema I, Falkenburg JHF.

Transplantation. 2017 Dec;101(12):2850-2854. doi: 10.1097/TP.0000000000001713.

PMID:
28252558
19.

Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.

Loeff FC, van Egmond HME, Nijmeijer BA, Falkenburg JHF, Halkes CJ, Jedema I.

Leuk Lymphoma. 2017 Sep;58(9):1-14. doi: 10.1080/10428194.2017.1281411. Epub 2017 Jan 31.

PMID:
28140725
20.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

21.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F.

Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27. No abstract available.

22.

Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia.

Tjon JM, de Groot MR, Sypkens Smit SMA, de Wreede LC, Snijders TJF, Koene HR, Meijer E, Raaijmakers MHG, Schaap M, Raymakers R, Zeerleder SS, Halkes CJM.

Br J Haematol. 2018 Feb;180(3):459-462. doi: 10.1111/bjh.14372. Epub 2016 Oct 7. No abstract available.

PMID:
27714765
23.

Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy.

von dem Borne PA, de Wreede LC, Halkes CJ, Marijt WA, Falkenburg JH, Veelken H.

Leuk Res. 2016 Jul;46:45-50. doi: 10.1016/j.leukres.2016.03.010. Epub 2016 Apr 9.

24.

Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.

Eefting M, de Wreede LC, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW, Veelken H, Putter H, Schetelig J, Falkenburg JH.

Haematologica. 2016 Apr;101(4):506-14. doi: 10.3324/haematol.2015.136846. Epub 2016 Jan 22.

25.

Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.

Halkes CJM, Zoutman WH, van der Fits L, Jedema I, Vermeer MH.

J Invest Dermatol. 2015 Apr;135(4):1199-1202. doi: 10.1038/jid.2014.501. Epub 2014 Nov 28. No abstract available.

26.

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.

Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, Boezeman JB, Marie JP, Halkes CJ, de Witte T, Huls G, Suciu S, Wevers RA, van der Reijden BA, Jansen JH; EORTC Leukemia Group and GIMEMA.

Blood. 2014 Aug 14;124(7):1110-8. doi: 10.1182/blood-2013-08-518514. Epub 2014 Jul 1.

PMID:
24986689
27.

PTX3 deficiency and aspergillosis.

de Boer MG, Halkes CJ, van de Vosse E.

N Engl J Med. 2014 Apr 24;370(17):1665-6. doi: 10.1056/NEJMc1402787. No abstract available.

PMID:
24758633
29.

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.

J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.

30.

Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.

Eefting M, von dem Borne PA, de Wreede LC, Halkes CJ, Kersting S, Marijt EW, Veelken H, Falkenburg JF.

Haematologica. 2014 Apr;99(4):751-8. doi: 10.3324/haematol.2013.089565. Epub 2013 Nov 15.

31.

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lübbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP.

J Clin Oncol. 2013 Dec 10;31(35):4424-30. doi: 10.1200/JCO.2013.49.0771. Epub 2013 Oct 14.

PMID:
24127442
32.

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL.

Eefting M, Halkes CJ, de Wreede LC, van Pelt CM, Kersting S, Marijt EW, von dem Borne PA, Willemze R, Veelken H, Falkenburg JH.

Bone Marrow Transplant. 2014 Feb;49(2):287-91. doi: 10.1038/bmt.2013.111. Epub 2013 Aug 12. Erratum in: Bone Marrow Transplant. 2014 Feb;49(2):320.

PMID:
23933760
33.

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH.

Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18.

PMID:
23777765
34.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Löwenberg B.

Blood. 2012 Dec 6;120(24):4706-11. doi: 10.1182/blood-2012-04-420596. Epub 2012 Oct 9.

PMID:
23047822
35.

Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.

Meij P, Jedema I, Zandvliet ML, van der Heiden PL, van de Meent M, van Egmond HM, van Liempt E, Hoogstraten C, Kruithof S, Veld S, Marijt EW, von dem Borne PA, Lankester AC, Halkes CJ, Falkenburg JH.

J Immunother. 2012 Oct;35(8):621-8.

PMID:
22996368
36.

Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.

Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, van Bergen CA, Marijt EW, Oudshoorn M, Griffioen M, Falkenburg JH.

Biol Blood Marrow Transplant. 2013 Jan;19(1):40-8. doi: 10.1016/j.bbmt.2012.07.020. Epub 2012 Aug 4.

37.

Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients.

van der Beek MT, Marijt EW, Vossen AC, van der Blij-de Brouwer CS, Wolterbeek R, Halkes CJ, Claas EC, Kroes AC.

Antivir Ther. 2012;17(1):45-51. doi: 10.3851/IMP1899.

PMID:
22267468
38.

Horse versus rabbit antithymocyte globulin in aplastic anemia.

Halkes CJ, Veelken H, Falkenburg JH.

N Engl J Med. 2011 Nov 10;365(19):1842-3; author reply 1843-4. doi: 10.1056/NEJMc1110228. No abstract available.

PMID:
22070489
39.

Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation.

de Boer MG, Jolink H, Halkes CJ, van der Heiden PL, Kremer D, Falkenburg JH, van de Vosse E, van Dissel JT.

PLoS One. 2011 Apr 4;6(4):e18403. doi: 10.1371/journal.pone.0018403.

40.

The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis.

Chai LY, de Boer MG, van der Velden WJ, Plantinga TS, van Spriel AB, Jacobs C, Halkes CJ, Vonk AG, Blijlevens NM, van Dissel JT, Donnelly PJ, Kullberg BJ, Maertens J, Netea MG.

J Infect Dis. 2011 Mar 1;203(5):736-43. doi: 10.1093/infdis/jiq102. Epub 2011 Jan 17.

41.

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.

Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH.

Blood. 2010 Dec 23;116(26):5930-40. doi: 10.1182/blood-2010-01-262006. Epub 2010 Sep 15.

PMID:
20844239
42.

Extreme leucocytosis: not always leukaemia.

Halkes CJ, Dijstelbloem HM, Eelkman Rooda SJ, Kramer MH.

Neth J Med. 2007 Jul-Aug;65(7):248-51.

43.
44.
45.
46.

In vivo regulation of plasma free fatty acids in insulin resistance.

Mook S, Halkes Cj Cj, Bilecen S, Cabezas MC.

Metabolism. 2004 Sep;53(9):1197-201.

PMID:
15334384
47.

Diurnal triglyceridaemia and insulin resistance in mildly obese subjects with normal fasting plasma lipids.

Halkes CJ, Van Wijk JP, Ribalta J, Masana L, Castro Cabezas M.

J Intern Med. 2004 Jan;255(1):74-81.

48.

Daytime triglyceridemia in normocholesterolemic patients with premature atherosclerosis and in their first-degree relatives.

Geluk CA, Halkes CJ, De Jaegere PP, Plokker TW, Cabezas MC.

Metabolism. 2004 Jan;53(1):49-53.

PMID:
14681841
49.

Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis.

van Wijk JP, Halkes CJ, De Jaegere PP, Plokker HW, Erkelens DW, Cabezas MC.

Atherosclerosis. 2003 Nov;171(1):109-16.

PMID:
14642412
50.

Gender differences in postprandial ketone bodies in normolipidemic subjects and in untreated patients with familial combined hyperlipidemia.

Halkes CJ, van Dijk H, Verseyden C, de Jaegere PP, Plokker HW, Meijssen S, Erkelens DW, Cabezas MC.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1875-80. Epub 2003 Aug 21.

PMID:
12933534

Supplemental Content

Loading ...
Support Center